ReviewResearch and practice in thrombosis and haemostasis2020
Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review.
Review in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper.World journal of emergency surgery : WJES · 2021Guideline
- Trial
- Viscoelastic testing: Transforming hemostasis management in patients in the medical intensive care unit.World journal of critical care medicine · 2026Review
- Overview of Inflammatory and Coagulation Markers in Elderly Patients with COVID-19: Retrospective Analysis of Laboratory Results.Life (Basel, Switzerland) · 2025Article
- Systemic reduced-dose alteplase for diffuse pulmonary thrombi in a COVID-19 patient.Clinical case reports · 2023Article
- Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis.BMJ open · 2023Article
- Article
- Case series of nebulizing r-tPA for COVID-19 induced acute respiratory distress syndrome.Clinical case reports · 2022Article
- COVID-19 coagulopathy - what should we treat?Experimental physiology · 2022Review
- In Situ Pulmonary Thrombolysis and Perfusion Lung Angiography in Severe COVID-19 Respiratory Failure.Critical care explorations · 2022Article
- Fibrinolytics as an ARDS Salvage Option: Promising, But ARDS Prevention Options Are Needed Urgently.Chest · 2022Article
- MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.Research and practice in thrombosis and haemostasis · 2022Article
- Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system.Acta biochimica et biophysica Sinica · 2022Review
- Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19.Science translational medicine · 2021Article
- Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.Annals of the American Thoracic Society · 2021Article
- Endothelial cells and SARS-CoV-2: An intimate relationship.Vascular pharmacology · 2021Review
- SARS-CoV-2: Targeted managements and vaccine development.Cytokine & growth factor reviews · 2021Review
- Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?Journal of thrombosis and thrombolysis · 2021Review
- The role of rotational thromboelastometry during the COVID-19 pandemic: a narrative review.Korean journal of anesthesiology · 2021Review
- Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19.Blood advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three quarters of patients with COVID-19 admitted to the intensive care unit, and both the clinical picture and pathologic findings are consistent with microvascular occlusive phenomena being a major contributor to their unique form of respiratory failure. Numerous studies are ongoing focusing on anticytokine therapies, antibiotics, and antiviral agents, but none to date have focused on treating the underlying thrombotic coagulopathy in an effort to improve respiratory failure in COVID-19. There are animal data and a previous human trial demonstrating a survival advantage with fibrinolytic therapy to treat acute respiratory distress syndrome. Here, we review the extant and emerging literature on the relationship between thrombotic coagulopathy and pulmonary failure in the context of COVID-19 and present the scientific rationale for consideration of targeting the coagulation and fibrinolytic systems to improve pulmonary function in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.